Medtronic plc

Medtronic plc is the world's largest standalone medical device company, designing, manufacturing, and servicing a portfolio that spans cardiac rhythm management, structural heart, neuromodulation, surgical robotics, and more than a dozen other therapy areas, generating $36.4 billion in GAAP revenue in its fiscal year ended April 24, 2026. Headquartered in Galway, Ireland, with operational leadership in Minneapolis, the company employs roughly 95,000 people and sells into more than 150 countries.

This is a story about a sprawling medical-technology conglomerate that spent a decade digesting the $50 billion Covidien merger and is now entering a chapter of deliberate focus. The March 2026 MiniMed IPO — separating a structurally lower-margin diabetes business into a standalone public company — is the clearest signal yet that management is narrowing the aperture toward the businesses where it has genuine competitive advantage and the ability to compound. At the same time, the company is enjoying the best top-line momentum it has seen in a decade, powered by a pulsed-field ablation (PFA) cycle in cardiac ablation that has turned an underappreciated asset into a $2 billion annualized growth engine.

The central question is whether the current growth impulse is durable enough to change the character of the enterprise. Medtronic has historically traded like a low-growth stalwart: reliable cash flows, a steady dividend, but no sustained organic acceleration. FY2026's 5.8% organic growth — and management's guidance for 5.8% at the midpoint in FY2027, excluding the extra selling week — suggests something may have shifted. The file turns on whether the portfolio's collection of growth drivers (CAS, renal denervation, Hugo robotics, Altaviva, Stealth AXiS) can collectively sustain mid-single-digit organic growth after the PFA cycle matures, and whether the margin profile improves as the company sheds Diabetes and laps tariff headwinds. The central tension is that Medtronic's portfolio breadth is both its greatest competitive advantage and its largest execution challenge — and the current moment may be the best opportunity in a decade to resolve that tension in shareholders' favor.